Hepatitis C incidence is low among Canadian men on PrEP
How do we deal with apparent cases of PrEP failure?
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
Options for two-drug simplification expand
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk
HIV-positive gay men in England report highest chemsex rates in four-country survey
Coalition of liver associations call for simplifying hepatitis C care
Dolutegravir and raltegravir cause changes to fat cells
Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts
